BAVA Bavarian Nordic A/S

Bavarian Nordic Announces Closing of Sale of Priority Review Voucher

Bavarian Nordic Announces Closing of Sale of Priority Review Voucher

COPENHAGEN, Denmark, January 27, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced the completion of the sale of its Priority Review Voucher (PRV) to an undisclosed buyer. Upon completion, the company received a cash consideration of USD 95 million.

For more information about the PRV sale, see .

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and has been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an investigational Ebola vaccine, licensed to Janssen. For more information visit .

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts

Rolf Sass Sørensen

Vice President Investor Relations (EU)

Tel:

Graham Morrell, Paddock Circle Advisors (US)



Tel:

Company Announcement no. 04 / 2020

Attachment

EN
27/01/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bavarian Nordic A/S

 PRESS RELEASE

Indberetning af ledende medarbejdere og disses nærtståendes transaktio...

Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer KØBENHAVN, Danmark, 12. marts 2026 – Bavarian Nordic A/S (OMX: BAVA) har dags dato modtaget oplysninger om følgende transaktioner med selskabets aktie/tilknyttede værdipapirer, foretaget af ledende medarbejdere og/eller personer/firmaer der er nærtstående til disse, hvilke hermed offentliggøres i overensstemmelse med §19 i Europa Parlamentets og Rådets forordning (EU) nr. 596/2014 samt Kommissionens Gennemførelsesforordning (EU) nr. 2016/523. Transaktionerne ved...

 PRESS RELEASE

Report of transactions of shares and related securities of Bavarian No...

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such COPENHAGEN, Denmark, March 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such, which are hereby reported in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523. The ...

 PRESS RELEASE

Bavarian Nordic lancerer næste del af aktietilbagekøbsprogram

Bavarian Nordic lancerer næste del af aktietilbagekøbsprogram KØBENHAVN, Danmark, 12. marts 2026 – Bavarian Nordic A/S (OMX: BAVA) iværksætter nu den anden del af det planlagte aktietilbagekøbsprogram, hvorunder selskabet vil tilbagekøbe egne aktier for op til DKK 500 mio. i løbet af 2026. Den første del, som blev afsluttet tidligt i februar 2026, omfattede tilbagekøb af aktier for DKK 150 mio. Den anden del vil omfatte tilbagekøb af aktier for op til DKK 200 mio., som selskabet også vil beholde som egne aktier med det formål at tilpasse kapitalstrukturen. Aktietilbagekøbsprogrammet iværk...

 PRESS RELEASE

Bavarian Nordic Launches Next Tranche of Share Buy-Back Program

Bavarian Nordic Launches Next Tranche of Share Buy-Back Program COPENHAGEN, Denmark, March 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the second tranche of the planned buy-back program, under which the Company intends to repurchase own shares for up to DKK 500 million during 2026. The first tranche, completed in early February 2026, comprised buy-back of shares for DKK 150 million. The second tranche will comprise buy-back of shares for DKK 200 million, also to be held as treasury stock for the purpose of adjusting the capital structure. The share buy-back program is initia...

 PRESS RELEASE

Bavarian Nordic offentliggør årsrapport for 2025

Bavarian Nordic offentliggør årsrapport for 2025 KØBENHAVN, Danmark, 12. marts 2026 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag årsrapporten for 2025. De konsoliderede og reviderede finansielle resultater var i overensstemmelse med de foreløbige resultater, der blev offentliggjort den 12. februar 2026. Årsrapporten er vedhæftet og er desuden tilgængelig via . “Vores årsrapport for 2025 bekræfter de stærke foreløbige resultater, vi rapporterede i sidste måned, og vi er godt i gang med at gennemføre vores planer for 2026 med henblik på at levere fortsat vækst i vores Travel Healt...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch